Busca avançada
Ano de início
Entree
(Referência obtida automaticamente do Web of Science, por meio da informação sobre o financiamento pela FAPESP e o número do processo correspondente, incluída na publicação pelos autores.)

Pharmaceutical grade chondroitin sulfate: Structural analysis and identification of contaminants in different commercial preparations

Texto completo
Autor(es):
da Cunha, Andre Luiz [1, 2] ; de Oliveira, Luiz Gustavo [2] ; Maia, Lenize Fernandes [3] ; Cappa de Oliveira, Luiz Fernando [3] ; Michelacci, Yara M. [1] ; de Aguiar, Jair Adriano K. [1, 2]
Número total de Autores: 6
Afiliação do(s) autor(es):
[1] Univ Fed Sao Paulo, Escola Paulista Med, Dept Bioquim, BR-04044020 Sao Paulo, SP - Brazil
[2] Univ Fed Juiz de Fora, Inst Ciencias Biol, Dept Bioquim, BR-36036900 Juiz De Fora, MG - Brazil
[3] Univ Fed Juiz de Fora, Inst Ciencias Exatas, Dept Quim, BR-36036900 Juiz de Fora, MG - Brazil
Número total de Afiliações: 3
Tipo de documento: Artigo Científico
Fonte: Carbohydrate Polymers; v. 134, p. 300-308, DEC 10 2015.
Citações Web of Science: 12
Resumo

The aim of the present study was to characterize 16 pharmaceutical grade chondroitin sulfate (CS) samples, concerning the structure and presence of contaminants, in comparison to USP and analytical grade CS. Agarose gel electrophoresis has shown that only 5 samples were >90% CS, while 11 contained less than 15% CS. FACE (fluorophore-assisted carbohydrate electrophoresis) revealed that maltodextrin was the main contaminant in nine of them, and lactose in two. Raman spectroscopy corroborated these results. Concerning the structure of the CS present in the five CS-rich samples, the ratios 4-sulfated:6-sulfated disaccharides varied from 0.9 to 1.7, and their modal molecular weight was 20-29 kDa. Also, they were all contaminated by small amounts of keratan sulfate (<1%). In conclusion, our findings indicate that the composition of CS preparations not always corresponds to the manufacturers' descriptions, and indicate that further characterization should be required for the registry and license of pharmaceutical grade CS. (C) 2015 Elsevier Ltd. All rights reserved. (AU)

Processo FAPESP: 10/16022-5 - Enzimas lisossomais, metaloproteinases e proteoglicanos em Diabetes mellitus
Beneficiário:Yara Maria Corrêa da Silva Michelacci
Modalidade de apoio: Auxílio à Pesquisa - Regular